Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

New laboratory method uses SALL4 gene to expand adult hematopoietic stem cells

Scientists discover key molecule that targets tumour blood vessels

Scientists discover key molecule that targets tumour blood vessels

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

GTx to initiate two Ostarine Phase III trial for treatment of muscle wasting in patients with NSCLC

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Incyte's ruxolitinib Phase III trial data on myelofibrosis presented at ASCO 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

EntreMed's ENMD-2076 Phase 2 trial data on platinum-resistant ovarian cancer presented at ASCO 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

National Cancer Survivors Day to be held on June 5th 2011

National Cancer Survivors Day to be held on June 5th 2011

Delayed treatment could prove effective in certain medical conditions

Delayed treatment could prove effective in certain medical conditions

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Media outlets examine case of man cured of HIV, leukemia through bone marrow transplant

Media outlets examine case of man cured of HIV, leukemia through bone marrow transplant

Scientists find no link between XMRV retrovirus and human disease

Scientists find no link between XMRV retrovirus and human disease

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

Mouse virus not responsible for Chronic Fatigue Syndrome, new study finds

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.